Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07814417) titled 'A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Colorectal Neoplasms
Intervention:
Drug: Olomorasib
Drug: Cetuximab
Drug: Oxaliplatin
Drug: Leucovorin/levofolinate calcium
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2026
Target Sample Size: 50
To know more, visit https://clinicaltrials....